![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/forvets-headline.png)
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/forvets-product.png)
The Facts
- Provides effective flea control within 8 hours after treatment. 1,2
- Continues to effectively kill newly arriving fleas within 8 hours, throughout the entire 3-month treatment interval. 1,2
- Reduces the incidence of flea allergy dermatitis by controlling adult fleas.
- Controls brown dog ticks for 8 weeks.
- Highly palatable tasty oral chew format.
- Can be used in puppies from 8 weeks of age and in breeding, pregnant and lactating dogs.
The Benefits
- Rapid and consistent tick and flea efficacy. 1,2,3
- Bravecto’s extended protection periods 3 mean clients have fewer treatments to remember each year, therefore less to forget.
- Bravecto gives immediate and persistent protection lasting the entire length of the flea lifecycle.
- No mess to administer, won’t wash or rub off.
- Peace of mind for your clients knowing their pet is protected.
- Simple dosing for increased convenience.
- MSD data on file.
- Taenzler J, Wengenmayer C et al. Onset of activity of fluralaner (Bravecto™) against Ctenocephalides felis on dogs. Parasites & Vectors (2014) 7:567.
- 3 months protection against fleas, 4 months protection against paralysis ticks and 8 weeks protection against brown dog ticks. Refer to label for foll claim details.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/forvets-sub.jpg)
Vet Resources:
Product Information
Clinical Papers
Our vision at MSD Animal Health is The Science of Healthier Animals, and Bravecto is a remarkable result of that vision.
This tick and flea treatment for dogs achieves the combination of highly potent insecticidal efficacy and persistent activity with a strong safety profile.
We are very proud to bring to you the following peer-reviewed publications, recognizing that these papers present just a fraction of the tremendous effort that went into developing and obtaining regulatory approval for Bravecto (fluralaner).
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Onset of activity of fluralaner (BRAVECTO™) against Ctenocephalides felis on dogs
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Efficacy of fluralaner flavored chews (Bravecto®) administered to dogs against the adult cat flea, Ctenocephalides felis and egg production
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Fluralaner, a novel isoxazoline, prevents flea (Ctenocephalides felis) reproduction in vitro and in a simulated home environment.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
A small-scale open-label study of the treatment of canine flea allergy dermatitis with fluralaner.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Open field study on the efficacy of oral fluralaner for long-term control of flea allergy dermatitis in client-owned dogs in Ile-de-France region
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
The speed of kill of fluralaner (Bravecto™) against Ixodes ricinus ticks on dogs.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Prevention of transmission of Babesia canis by Dermacentor reticulatus ticks to dogs treated orally with fluralaner chewable tablets (Bravecto™).
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Plasma pharmacokinetic profile of fluralaner (Bravecto™) and ivermectin following concurrent administration to dogs.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
A quantitative evaluation of the extent of fluralaner uptake by ticks (Ixodes ricinus, Ixodes scapularis) in fluralaner (Bravecto™) treated vs. untreated dogs using the parameters tick weight and coxal index.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Fluralaner activity against life stages of ticks using Rhipicephalus sanguineus and Ornithodoros moubata IN in vitro contact and feeding assays.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
A randomized, blinded, controlled USA field study to assess the use of fluralaner tablets in controlling canine flea infestations.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto™ (fluralaner) against FrontlineTM (fipronil) in flea- and tick-infested dogs.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
A randomized controlled trial of the efficacy of orally administered fluralaner (Bravecto™) against induced Ixodes holocyclus (Australian paralysis tick) infestations on dogs.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Safety of concurrent treatment of dogs with fluralaner (Bravecto™) and milbemycin oxime – praziquantel.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Safety of the concurrent treatment of dogs with Bravecto™ (fluralaner) and Scalibor™ protectorband (deltamethrin).
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Safety of fluralaner chewable tablets (Bravecto™), a novel systemic antiparasitic drug, in dogs after oral administration.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Safety of fluralaner, a novel systemic antiparasitic drug, in MDR1(-/-) Collies after oral administration.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
Pharmacokinetics of fluralaner in dogs following a single oral or intravenous administration.
![](https://www.bravecto.com.ph/wp-content/uploads/sites/41/2021/05/icon-pdf-w38.png)
The effect of food on the pharmacokinetics of oral fluralaner in dogs.